Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Antioxidant May Disrupt Alzheimer's Disease… >
Antioxidant May Disrupt Alzheimer's Disease Process

Published: April 10, 2012.
By IOS Press
http://www.iospress.com

Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.

In the current study a group of investigators from led by Dr. Othman Ghribi, PhD, Associate Professor, Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota School of Medicine and Health Sciences, rabbits were fed a high-cholesterol diet which caused them to accumulate plaques of a small protein called beta-amyloid (Aβ). These plaques are toxic to neurons and central to the development of Alzheimer's disease. The rabbits also developed changes in tau protein, which is part of the skeleton of neurons. When this protein becomes heavily phosphorylated, the ability of neurons to conduct electrical signals is disrupted. Following treatment with a drug called deferiprone (an iron chelator), the iron level in the rabbits' blood plasma was reduced and the levels of both beta-amyloid and phosphorylated tau in the brain were returned to normal levels.

Another degenerative process in AD involves the production of reactive oxygen species (ROS) that can damage neurons in the brain. Deferiprone is also thought to suppress this reactive oxygen damage caused by free iron in the bloodstream, however in this study there was no difference in reactive oxygen species in the treated group. It appears that iron in the AD brain is located in the wrong places – in particular it accumulates to very high levels in the cores of beta-amyloid plaques and is very reactive in this setting.

According to Dr. Ghribi, "Our data show that treatment with the iron chelator deferiprone opposes several pathological events induced by a cholesterol-enriched diet…Deferiprone reduced the generation of Aβ and lowered levels of tau phosphorylation." While there was no effect on ROS levels, he comments that "It is possible that a higher dose of deferiprone, or combination therapy of deferiprone together with an antioxidant to prevent ROS generation would more-fully protect against the deleterious effects of cholesterol-enriched diet that are relevant to AD pathology."

Noted expert on metals metabolism research on AD Ashley Bush, MD, PhD, Mental Health Research Institute, Melbourne, Australia, adds that "this research highlights the role of metal ions as key modulators for the toxic interactions of risk factors for Alzheimer's disease, in this case cholesterol. Drugs targeting these metal interactions hold promise as disease-modifying agents."



Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Early 
8/19/13 
★★★ 
Brain Network Decay Detected in Early Alzheimer's
By Washington University School of Medicine
In patients with early Alzheimer's disease, disruptions in brain networks emerge about the same time as chemical markers of the disease appear in the spinal fluid, researchers at Washington …
Networks 
9/18/12 
★★★ 
Alzheimer's Breaks Brain Networks' Coordination
By Washington University School of Medicine
Scientists at Washington University School of Medicine in St. Louis have taken one of the first detailed looks into how Alzheimer's disease disrupts coordination among several of the brain's …
Risk 
1/3/12 
Alzheimer's Damage Occurs Early
By Lund University
Physician Oskar Hansson and his research group are studying biomarkers – substances present in spinal fluid and linked to Alzheimer's disease. The group has studied close to 140 people …
Sweden 
3/23/12 
A New Test Might Facilitate Diagnosis And Drug Development for Alzheimer's Disease
By IOS Press
An international team of researchers have developed a new method for measurement of aggregated beta-amyloid – a protein complex believed to cause major nerve cell damage and dysfunction in …
Patients 
4/13/10 
Investigational Immune Intervention Slows Brain Shrinkage in Alzheimer's Patients
By New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
TORONTO (April 13, 2010) -- An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients …
Neugrid 
7/16/10 
neuGRID Project
By neuGRID Consortium
Alzheimer’s Disease goes on the web The extensive availability and accessibility of data in any field of the human knowledge, from humanities to medicine, can be accounted as …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition